SAN DIEGO, Jan. 07, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 9:30 a.m. US PST on Thursday, January 14, 2016. The conference is being held January 11th through 14th at The Westin St. Francis Hotel in San Francisco, California.
The presentation materials delivered at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com on the day of the presentation. A copy of the presentation materials will also be lodged with the Australian Securities Exchange and filed with the U.S. Securities and Exchange Commission.
About REVA
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.
United States Investor & Media Enquiries: REVA Medical, Inc. Cheryl Liberatore Director, Communications +1 858-966-3045 Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 2 9229 2700 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722 Annabel Murphy +61 2 9237 2800


TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 



